BSE: 524768 | NSE: | Pharmaceuticals & Drugs | Small Cap
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | TTM | |||
| ROCE % ⓘ | -0.3% | -8.8% | -17% | -8% | 15.7% | 79.1% | 36.1% | 22.4% | 23.9% | 29.1% | - | ||
| Value Creation Index ⓘ | -1.0 | -1.6 | -2.2 | -1.6 | 0.1 | 4.7 | 1.6 | 0.6 | 0.7 | 1.1 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 3.2 | 0.6 | 1.4 | 2.2 | 2 | 2.6 | 1.3 | 0.6 | 3.4 | 7 | 6 | ||
| YoY Gr. Rt. % | - | -81.9% | 136.2% | 59.9% | -10.1% | 33.5% | -52.5% | -49.6% | 439.7% | 105.6% | - | ||
| Adj EPS ⓘ | -0 | -0.4 | -0.6 | -0.2 | 0.4 | 2.4 | 1.8 | 1.5 | 1.9 | 2.9 | 2.5 | ||
| YoY Gr. Rt. % | - | NA | NA | NA | NA | 555.6% | -22.5% | -19.7% | 27.9% | 54.3% | - | ||
| BVPS (₹) ⓘ | 4.2 | 3.8 | 3.2 | 2.8 | 1.8 | 4.2 | 6 | 7 | 8.5 | 11.4 | 12 | ||
| Adj Net Profit ⓘ | 0 | -0.2 | -0.3 | -0.1 | 0.2 | 1.2 | 0.9 | 0.7 | 0.9 | 1.5 | 1 | ||
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | 0 | 0.4 | 0.8 | 0.7 | 0.4 | 1 | 0.5 | - | ||
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.2 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 9.1% | 28.8% | 77.5% | 105.6% | ||||||||
| Adj EPS ⓘ | NA | 51.8% | 16.6% | 54.3% | ||||||||
| BVPS ⓘ | 11.9 | 44.4 | 24.1 | 33.8 | ||||||||
| Share Price | 28.1% | 12.8% | 26% | 89.1% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | TTM | ||
| Return on Equity % ⓘ | -0.4 | -8.9 | -17.1 | -8.1 | 15.6 | 78.6 | 36 | 22.6 | 24.1 | 29.1 | 21.2 | |
| Op. Profit Mgn % ⓘ | 0.1 | -32.9 | -3.9 | -6.5 | 0.6 | 8.6 | -33.3 | -101.6 | -11.9 | 12.1 | 7.2 | |
| Net Profit Mgn % ⓘ | -0.3 | -31.4 | -22 | -5.5 | 9 | 44.8 | 72.9 | 116.5 | 27.6 | 20.7 | 21.8 | |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Working Cap Days ⓘ | 307 | 1,828 | 477 | 126 | 175 | 152 | 333 | 905 | 193 | 124 | 11,455 | |
| Cash Conv. Cycle ⓘ | 14 | 362 | 76 | 63 | 64 | 40 | 39 | 187 | 47 | 57 | 10,075 | |
Sales growth is growing at healthy rate in last 3 years 77.50%
Net Profit is growing at healthy rate in last 3 years 16.59%
Sales growth is good in last 4 quarters at 81.09%
Return on Equity has declined versus last 3 years average to 21.20%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.5 | - |
| TTM Sales (₹ Cr.) | 5.7 | - |
| BVPS (₹.) ⓘ | 12 | - |
| Reserves (₹ Cr.) ⓘ | 1 | - |
| P/BV ⓘ | 3.06 | - |
| PE ⓘ | 14.77 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 13.80 / 55.65 |
| All Time Low / High (₹) | 1.00 / 55.65 |
| Market Cap (₹ Cr.) | 18.3 |
| Equity (₹ Cr.) | 5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.9 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Emmessar Biotech & Nutrition Ltd., was originally started as Emmessar Chemical Industries Ltd on March 17,1992, for manufacturing Super Speciality Fine Chemicals. The Company succeeded in developing many Speciality Fine Chemicals in its own In-house R&D, which was recognised on January 15, 1996 by DSIR, Ministry of Science & Technology, Government of India, New Delhi .
When there was a realisation that some of the Speciality Chemicals developed in our R&D and exported to USA & Europe were being used in Healthcare formulations, the Company decided to re-orient itself and enter the Healthcare business, which is poised for phenomenal growth in the coming decades.
Concurrently the company also realised that some of the Speciality Chemicals are actually Vital Micro Nutrients, which are being used in the research worldwide as tools of Biotechnology, the Company took a conscious decision to enter the field of Biotechnology & Healthcare.
To ensure that the name is representative of its activity, the company's name was changed from Emmessar Chemical Industries Ltd., to Emmessar Biotech & Nutrition Ltd., on 7th April 2000.
In the process of pursuing its own R&D and exploring commercial market potentials for their products in the field of Healthcare, the company came across another reputed company in USA Vibrant Life in California.
Intense exchange of ideas & technical information between Emmessar Biotech & Nutrition Ltd., & Vibrant Life, resulted in development of several new concepts and new technologies - combining different schools of thought such as Nutraceuticals, Cosmeceuticals, Ayurveda & Biotechnology.
The company has developed many products covering different areas of healthcare that include obstinate Skin problems & debilitating chronic physical ailments.
Emmessar Biotech & Nutrition Ltd., is a Public Limited Company, with the Paid-up Share Capital of about Rs. 50.00 million (over $ 1.00 million). The Stocks of Emmessar Biotech & Nutrition Ltd., are traded in The Bombay Stock Exchange Ltd.
Product range of the company includes:
Present products
Products planned to be launched in future
My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
